Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium thiosulfate for calcinosis cutis in systemic sclerosis
2023-510255-34-00Phase 4Authorised
- Sponsor
- Aarhus University Hospital
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in calcinosis cutis, systemic sclerosis (SSc) and mixed connective tissue disease (MCTD) comparing Intralesional sodium thiosulfate with Control / standard of care (2 arms). Primary endpoints: Complete remission of calcinosis cutis from week 0 to week 28 and Partial remission of calcinosis cutis from week 0 to week 28. Planned start May 2024; status: authorised.
02
Drugs
sodium thiosulfate
03
Conditions
calcinosis cutissystemic sclerosis (SSc)mixed connective tissue disease (MCTD)
Beyond the preview
Go deeper on 2023-510255-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510255-34-00.